Cellectis Financial Statements From 2010 to 2025
| CMVLF Stock | USD 1.25 0.00 0.00% |
Check Cellectis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cellectis' main balance sheet or income statement drivers, such as , as well as many indicators such as . Cellectis financial statements analysis is a perfect complement when working with Cellectis Valuation or Volatility modules.
Cellectis |
Cellectis SA Company Current Valuation Analysis
Cellectis' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cellectis Current Valuation | 82.79 M |
Most of Cellectis' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cellectis SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cellectis SA has a Current Valuation of 82.79 M. This is 99.42% lower than that of the Healthcare sector and 98.22% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.5% higher than that of the company.
Cellectis SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cellectis's current stock value. Our valuation model uses many indicators to compare Cellectis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cellectis competition to find correlations between indicators driving Cellectis's intrinsic value. More Info.Cellectis SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cellectis' earnings, one of the primary drivers of an investment's value.About Cellectis Financial Statements
Cellectis stakeholders use historical fundamental indicators, such as Cellectis' revenue or net income, to determine how well the company is positioned to perform in the future. Although Cellectis investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cellectis' assets and liabilities are reflected in the revenues and expenses on Cellectis' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cellectis SA. Please read more on our technical analysis and fundamental analysis pages.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis Romainvil operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 294 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Cellectis Pink Sheet
When determining whether Cellectis SA is a strong investment it is important to analyze Cellectis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cellectis' future performance. For an informed investment choice regarding Cellectis Pink Sheet, refer to the following important reports:Check out the analysis of Cellectis Correlation against competitors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.